Balyasny Asset Management
ATNM icon

Balyasny Asset Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Balyasny Asset Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-352
Closed -$34K – 1262
2015
Q4 		$34K Sell
352
-18
-5% -$1.2K ﹤0.01% 1196
2015
Q3 		$20K Buy
+370
New +$24.7K ﹤0.01% 1113

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Balyasny Asset Management's ATNM Position: Q1 2016 in Review

Balyasny Asset Management sold out of Actinium Pharmaceuticals (ATNM) in Q1 2016, closing a stake of 352 shares — an estimated $34K sold.

Balyasny Asset Management first reported a position in ATNM in Q3 2015 and held it in 2 quarters. The position peaked at $34K in Q4 2015. 30 funds tracked by Wall St. Rank hold ATNM as of Q1 2016.

  • Balyasny Asset Management reported no remaining Actinium Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Balyasny Asset Management sold 352 Actinium Pharmaceuticals shares in Q1 2016, an estimated $34K.
  • Balyasny Asset Management first reported a position in Actinium Pharmaceuticals in Q3 2015 and held it in 2 quarters.
  • Balyasny Asset Management's Actinium Pharmaceuticals position peaked at $34K in Q4 2015.
  • 30 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2016.

Based on Balyasny Asset Management's 13F filing for Q1 2016, filed 16 May 2016.